|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:1990
|
|
gptkbp:atccode
|
N06 BA04
|
|
gptkbp:brand
|
gptkb:Methylphenidate
|
|
gptkbp:casnumber
|
298-00-0
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:chemical_formula
|
C14 H19 NO2
|
|
gptkbp:clinical_trial
|
cognitive function
behavioral assessment
long-term safety
ADHD treatment
|
|
gptkbp:contraindication
|
gptkb:Ophthalmology
tics
history of drug abuse
severe anxiety
|
|
gptkbp:dosage_form
|
extended-release tablet
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:tablet
oral solution
chewable tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Methylin
|
|
gptkbp:ingredients
|
gptkb:Sannin
|
|
gptkbp:interacts_with
|
antidepressants
MAO inhibitors
antihypertensives
anticonvulsants
|
|
gptkbp:legal_status
|
prescription only
|
|
gptkbp:lifespan
|
2 to 4 hours
|
|
gptkbp:manufacturer
|
gptkb:UCB,_Inc.
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patient_population
|
gptkb:children
adults
adolescents
|
|
gptkbp:related_to
|
gptkb:Ritalin
|
|
gptkbp:research_focus
|
drug interactions
neuropharmacology
ADHD management
side effect profile
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
anxiety
nausea
insomnia
loss of appetite
|
|
gptkbp:toxicity
|
moderate
|
|
gptkbp:type_of_care
|
improved with extended-release
|
|
gptkbp:used_for
|
attention deficit hyperactivity disorder
|
|
gptkbp:bfsParent
|
gptkb:Sannin
|
|
gptkbp:bfsLayer
|
5
|